Targeting Receptor Tyrosine Kinases in Solid Tumors

Surgical Oncology Clinics of North America

Volumn 22, Issue 4, 2013, Pages 685-703

  Zhang, Jianliang ^a   Hochwald, Steven N ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cancer; Solid tumors; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; CYTOTOXIC AGENT; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; LAPATINIB; NECITUMUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; PROTEIN TYROSINE KINASE; REGORAFENIB; SUNITINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VASCULOTROPIN; VEMURAFENIB;

ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVATION; ESOPHAGUS CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; METASTATIC COLORECTAL CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PROSTATE CANCER; PROTEIN FUNCTION; RECURRENT CANCER; RECURRENT DISEASE; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR; STOMACH CANCER; STOMATITIS; TUMOR INVASION; TUMOR VASCULARIZATION;

CANCER; SOLID TUMORS; TYROSINE KINASE INHIBITORS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84883554662     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.06.010     Document Type: Review

References (110)

1. Hamid O. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. JAm Pharm Assoc (2003) 2004, 44(1):52-58.
2. Robinson D.R., Wu Y.M., Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene 2000, 19(49):5548-5557.
3. Sharma P.S., Sharma R., Tyagi T. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr Pharm Des 2009, 15(7):758-776.
4. Cassier P.A., Fumagalli E., Rutkowski P., et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012, 18(16):4458-4464.
5. Sivendran S., Liu Z., Portas L.J., et al. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev 2012, 38(7):919-925.
6. Yang B., Papoian T. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome. JAppl Toxicol 2012, 32(12):945-951.
7. Hartman Z., Zhao H., Agazie Y.M. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Oncogene 2012, [Epub ahead of print].
8. Dhomen N.S., Mariadason J., Tebbutt N., et al. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog 2012, 17(1):31-50.
9. Ji H., Sharpless N.E., Wong K.K. EGFR targeted therapy: view from biological standpoint. Cell Cycle 2006, 5(18):2072-2076.
10. Lorenzo G.D., Bianco R., Tortora G., et al. Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin Prostate Cancer 2003, 2(1):50-57.
11. Franklin W.A., Veve R., Hirsch F.R., et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002, 29(1 Suppl 4):3-14.
12. Maihle N.J., Baron A.T., Barrette B.A., et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 2002, 107:247-258.
13. Fassan M., Ludwig K., Pizzi M., et al. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol 2012, 43(8):1206-1212.
14. Kurebayashi J. Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer 2001, 8(1):45-51.
15. Tan M., Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol 2007, 608:119-129.
16. Nielsen D.L., Kumler I., Palshof J.A., et al. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 2013, 22(1):1-12.
17. Jakobsson L., Franco C.A., Bentley K., et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol 2010, 12(10):943-953.
18. Gerhardt H., Golding M., Fruttiger M., et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. JCell Biol 2003, 161(6):1163-1177.
19. Davis S.L., Eckhardt S.G., Messersmith W.A., et al. The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today (Barc) 2013, 49(2):105-115.
20. Cabebe E., Wakelee H. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Drugs Today (Barc) 2006, 42(6):387-398.
21. Tsao A.S., Wei W., Kuhn E., et al. Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-beta) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer 2011, 12(6):369-374.
22. Coutts J.C., Gallagher J.T. Receptors for fibroblast growth factors. Immunol Cell Biol 1995, 73(6):584-589.
23. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10(2):116-129.
24. Wesche J., Haglund K., Haugsten E.M. Fibroblast growth factors and their receptors in cancer. Biochem J 2011, 437(2):199-213.
25. Cotton L.M., O'Bryan M.K., Hinton B.T. Cellular signaling by fibroblast growth factors (FGFs) and their receptors (FGFRs) in male reproduction. Endocr Rev 2008, 29(2):193-216.
26. Sonnenberg E., Meyer D., Weidner K.M., et al. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. JCell Biol 1993, 123(1):223-235.
27. Nusrat A., Parkos C.A., Bacarra A.E., et al. Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epithelium. JClin Invest 1994, 93(5):2056-2065.
28. Chmielowiec J., Borowiak M., Morkel M., et al. c-Met is essential for wound healing in the skin. JCell Biol 2007, 177(1):151-162.
29. Tang M.K., Zhou H.Y., Yam J.W., et al. c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia 2010, 12(2):128-138.
30. Sawada K., Radjabi A.R., Shinomiya N., et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007, 67(4):1670-1679.
31. Yu J., Ohuchida K., Mizumoto K., et al. Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol 2006, 12(24):3878-3882.
32. Moser C., Schachtschneider P., Lang S.A., et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer 2008, 44(11):1577-1586.
33. Resnik J.L., Reichart D.B., Huey K., et al. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998, 58(6):1159-1164.
34. Warshamana-Greene G.S., Litz J., Buchdunger E., et al. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2005, 11(4):1563-1571.
35. Putz T., Culig Z., Eder I.E., et al. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 1999, 59(1):227-233.
36. Ackermann M., Morse B.A., Delventhal V., et al. Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing's sarcoma A673-xenograft growth and normalize tumor vascular architecture. Angiogenesis 2012, 15(4):685-695.
37. Menu E., Jernberg-Wiklund H., De Raeve H., et al. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer 2007, 121(8):1857-1861.
38. Kucab J.E., Dunn S.E. Role of IGF-1R in mediating breast cancer invasion and metastasis. Breast Dis 2003, 17:41-47.
39. Garg N., Thakur S., McMahan C.A., et al. High fat diet induced insulin resistance and glucose intolerance are gender-specific in IGF-1R heterozygous mice. Biochem Biophys Res Commun 2011, 413(3):476-480.
40. Olianas M.C., Dedoni S., Onali P. delta-Opioid receptors stimulate GLUT1-mediated glucose uptake through Src- and IGF-1 receptor-dependent activation of PI3-kinase signalling in CHO cells. Br J Pharmacol 2011, 163(3):624-637.
41. Shang Y., Mao Y., Batson J., et al. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther 2008, 7(9):2599-2608.
42. Zhong D., Xiong L., Liu T., et al. The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. JBiol Chem 2009, 284(35):23225-23233.
43. Guha M., Srinivasan S., Biswas G., et al. Activation of a novel calcineurin-mediated insulin-like growth factor-1 receptor pathway, altered metabolism, and tumor cell invasion in cells subjected to mitochondrial respiratory stress. JBiol Chem 2007, 282(19):14536-14546.
44. Yarden Y., Kuang W.J., Yang-Feng T., et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987, 6(11):3341-3351.
45. Kapur R., Cooper R., Zhang L., et al. Cross-talk between alpha(4)beta(1)/alpha(5)beta(1) and c-Kit results in opposing effect on growth and survival of hematopoietic cells via the activation of focal adhesion kinase, mitogen-activated protein kinase, and Akt signaling pathways. Blood 2001, 97(7):1975-1981.
46. Broudy V.C., Morgan D.A., Lin N., et al. Stem cell factor influences the proliferation and erythroid differentiation of the MB-02 human erythroleukemia cell line by binding to a high-affinity c-kit receptor. Blood 1993, 82(2):436-444.
47. Tuveson D.A., Willis N.A., Jacks T., et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001, 20(36):5054-5058.
48. Tsuura Y., Hiraki H., Watanabe K., et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994, 424(2):135-141.
49. Regan J.L., Kendrick H., Magnay F.A., et al. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer. Oncogene 2012, 31(7):869-883.
50. Micke P., Hengstler J.G., Albrecht H., et al. c-kit expression in adenocarcinomas of the lung. Tumour Biol 2004, 25(5-6):235-242.
51. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279(5350):577-580.
52. Taniguchi M., Nishida T., Hirota S., et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999, 59(17):4297-4300.
53. Demetri G.D. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001, 28(5 Suppl 17):19-26.
54. Lee D.U., Jessen B. Off-target immune cell toxicity caused by AG-012986, a pan-CDK inhibitor, is associated with inhibition of p38 MAPK phosphorylation. JBiochem Mol Toxicol 2012, 26(3):101-108.
55. Renninger J.P., Murphy D.J., Morel D.W. Aselective Akt inhibitor produces hypotension and bradycardia in conscious rats due to inhibition of the autonomic nervous system. Toxicol Sci 2012, 125(2):578-585.
56. Borner M., Koeberle D., Von Moos R., et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 2008, 19(7):1288-1292.
57. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. JClin Oncol 2009, 27(5):663-671.
58. Dewdney A., Cunningham D., Tabernero J., et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). JClin Oncol 2012, 30(14):1620-1627.
59. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. NEngl J Med 2008, 359(11):1116-1127.
60. Lv S., Teugels E., Sadones J., et al. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int J Oncol 2012, 41(3):1029-1035.
61. Carey L.A., Rugo H.S., Marcom P.K., et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. JClin Oncol 2012, 30(21):2615-2623.
62. Hurt C.N., Nixon L.S., Griffiths G.O., et al. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 2011, 11:466.
63. Dienstmann R., Felip E. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther 2011, 11(9):1223-1231.
64. Kuenen B., Witteveen P.O., Ruijter R., et al. Aphase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010, 16(6):1915-1923.
65. Socinski M.A. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res 2007, 13(15 Pt 2):s4597-s4601.
66. Weiner L.M., Belldegrun A.S., Crawford J., et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008, 14(2):502-508.
67. Boyraz B., Sendur M.A., Aksoy S., et al. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin 2013, 29(4):405-414.
68. Dent S., Oyan B., Honig A., et al. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treat Rev 2013, 39(6):622-631.
69. Goss P.E., Smith I.E., O'Shaughnessy J., et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013, 14(1):88-96.
70. Walters D.M., Lindberg J.M., Adair S.J., et al. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia 2013, 15(2):143-155.
71. Aizawa M., Nagatsuma A.K., Kitada K., et al. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer 2013, [Epub ahead of print].
72. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
73. Verma S., Miles D., Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. NEngl J Med 2012, 367(19):1783-1791.
74. Cortes J., Fumoleau P., Bianchi G.V., et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. JClin Oncol 2012, 30(14):1594-1600.
75. Stevenson J.P., Langer C.J., Somer R.A., et al. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Cancer 2012, 118(22):5580-5587.
76. Lang I., Brodowicz T., Ryvo L., et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 2013, 14(2):125-133.
77. Bisagni G., Musolino A., Panebianco M., et al. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. Cancer Chemother Pharmacol 2013, 71(4):1051-1057.
78. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. JClin Oncol 2009, 27(5):740-745.
79. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370(9605):2103-2111.
80. Perren T.J., Swart A.M., Pfisterer J., et al. Aphase 3 trial of bevacizumab in ovarian cancer. NEngl J Med 2011, 365(26):2484-2496.
81. Ogita S., Tejwani S., Heilbrun L., et al. Pilot phase II trial of bevacizumab monotherapy in nonmetastatic castrate-resistant prostate cancer. ISRN Oncol 2012, 2012:242850.
82. Kelly W.K., Halabi S., Carducci M., et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. JClin Oncol 2012, 30(13):1534-1540.
83. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. NEngl J Med 2009, 361(10):947-957.
84. Cohen M.H., Johnson J.R., Chattopadhyay S., et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist 2010, 15(12):1344-1351.
85. Heinemann V., Vehling-Kaiser U., Waldschmidt D., et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013, 62(5):751-759.
86. Grothey A. Regorafenib in metastatic colorectal cancer. Clin Adv Hematol Oncol 2012, 10(5):324-325.
87. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncology (Williston Park) 2012, 26(10):896.
88. George S., Wang Q., Heinrich M.C., et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. JClin Oncol 2012, 30(19):2401-2407.
89. Cui J.J., Tran-Dube M., Shen H., et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). JMed Chem 2011, 54(18):6342-6363.
90. Rodig S.J., Shapiro G.I. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs 2010, 11(12):1477-1490.
91. Wallander M.L., Geiersbach K.B., Tripp S.R., et al. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 2012, 136(7):796-803.
92. O'Bryant C.L., Wenger S.D., Kim M., et al. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother 2013, 47(2):189-197.
93. George R.E., Sanda T., Hanna M., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455(7215):975-978.
94. Trial watch: success for crizotinib in ALK-driven cancer. Nat Rev Drug Discov 2010, 9(12):908.
95. Patrawala S., Puzanov I. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncol 2012, 8(5):509-523.
96. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEngl J Med 2011, 364(26):2507-2516.
97. Hiles J.J., Kolesar J.M. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 2008, 65(2):123-131.
98. Faivre S., Zappa M., Vilgrain V., et al. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res 2011, 17(13):4504-4512.
99. Raymond E., Dahan L., Raoul J.L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. NEngl J Med 2011, 364(6):501-513.
100. Delbaldo C., Faivre S., Dreyer C., et al. Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential. Ther Adv Med Oncol 2012, 4(1):9-18.
101. Blumenthal G.M., Cortazar P., Zhang J.J., et al. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist 2012, 17(8):1108-1113.
102. Harvey R.D., Owonikoko T.K., Lewis C.M., et al. Aphase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. Br J Cancer 2013, 108(4):762-765.
103. Gabardi S., Baroletti S.A. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010, 30(10):1044-1056.
104. Anandappa G., Hollingdale A., Eisen T. Everolimus-a new approach in the treatment of renal cell carcinoma. Cancer Manag Res 2010, 2:61-70.
105. Oudard S., Thiam R., Fournier L.S., et al. Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study. Eur J Cancer 2012, 48(10):1512-1518.
106. Calvo E., Escudier B., Motzer R.J., et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2012, 48(3):333-339.
107. Grunwald V., Karakiewicz P.I., Bavbek S.E., et al. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer 2012, 48(3):324-332.
108. Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. NEngl J Med 2011, 364(6):514-523.
109. Pavel M.E., Hainsworth J.D., Baudin E., et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378(9808):2005-2012.
110. Zhang J., Francois R., Iyer R., et al. Current understanding of the molecular biology of pancreatic neuroendocrine tumors (PanNETs). J Natl Cancer Inst 2013, 105(14):1005-1017.